Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1988 2
1989 4
1990 5
1991 1
1992 5
1994 8
1995 10
1996 5
1997 3
1998 8
1999 13
2000 12
2001 10
2002 17
2003 23
2004 14
2005 26
2006 24
2007 26
2008 25
2009 21
2010 28
2011 41
2012 40
2013 23
2014 41
2015 31
2016 39
2017 49
2018 43
2019 54
2020 60
2021 54
2022 47
2023 47
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

754 results

Results by year

Filters applied: . Clear all
Page 1
Primary central nervous system lymphoma.
Schaff LR, Grommes C. Schaff LR, et al. Blood. 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. Blood. 2022. PMID: 34699590 Free PMC article. Review.
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. The diagnosis of PCNSL requires a …
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects …
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T, Liu Y, Wang Y, Chang Q, Wu J, Wang Z, Geng D, Yu JT, Li Y, Li XQ, Chen H, Zhuang D, Li J, Wang B, Jiang T, Lyu L, Song Y, Qiu X, Li W, Lin S, Zhang X, Lu D, Lei J, Chen Y, Mao Y. Chen T, et al. J Hematol Oncol. 2022 Sep 29;15(1):136. doi: 10.1186/s13045-022-01356-7. J Hematol Oncol. 2022. PMID: 36176002 Free PMC article. Review.
Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. ...Mini-mental status examination can be used to assess cogn …
Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgki …
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Narita Y, et al. Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. Neuro Oncol. 2021. PMID: 32583848 Free PMC article. Clinical Trial.
BACKGROUND: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton's tyrosine kinase inhibitor, were evaluated for relapsed/refractory primary central nervous system lymphoma ( …
BACKGROUND: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton's ty …
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
Barajas RF, Politi LS, Anzalone N, Schöder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS. Barajas RF, et al. Neuro Oncol. 2021 Jul 1;23(7):1056-1071. doi: 10.1093/neuonc/noab020. Neuro Oncol. 2021. PMID: 33560416 Free PMC article.
Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, stagin …
Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNS …
Primary Central Nervous System Lymphomas.
Chukwueke U, Grommes C, Nayak L. Chukwueke U, et al. Hematol Oncol Clin North Am. 2022 Feb;36(1):147-159. doi: 10.1016/j.hoc.2021.09.004. Hematol Oncol Clin North Am. 2022. PMID: 34801161 Review.
Primary central nervous system lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma restricted to the brain, spinal cord, cerebrospinal fluid, and eyes. ...Recent molecular insights underlying the pathophysiology of PCNSL have led t …
Primary central nervous system lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma restrict …
Tirabrutinib: First Approval.
Dhillon S. Dhillon S. Drugs. 2020 Jun;80(8):835-840. doi: 10.1007/s40265-020-01318-8. Drugs. 2020. PMID: 32382949 Review.
In March 2020, oral tirabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabrutinib is also under regulatory review in Japan for the treatment of Waldenstrom's macroglobulinem …
In March 2020, oral tirabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous …
Primary Central Nervous System Lymphoma.
Löw S, Batchelor TT. Löw S, et al. Semin Neurol. 2018 Feb;38(1):86-94. doi: 10.1055/s-0038-1627470. Epub 2018 Mar 16. Semin Neurol. 2018. PMID: 29548055 Review.
Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma limited to the brain, spinal cord, leptomeninges, and eyes. ...
Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma limited to the brai …
Central Nervous System Lymphoma: Novel Therapies.
Fortin Ensign SP, Gathers D, Wiedmeier JE, Mrugala MM. Fortin Ensign SP, et al. Curr Treat Options Oncol. 2022 Jan;23(1):117-136. doi: 10.1007/s11864-021-00921-5. Epub 2022 Feb 19. Curr Treat Options Oncol. 2022. PMID: 35182298 Review.
In addition, the use of molecular profiling to predict disease response to targeted agents and understand relapse patterns will become increasingly important. Clinical trials in PCNSL are critical yet frequently challenging to conduct given the rarity of the condition and …
In addition, the use of molecular profiling to predict disease response to targeted agents and understand relapse patterns will become incre …
Natalizumab-Associated Primary Central Nervous System Lymphoma.
Nixon M, Menger RP, Kalakoti P, Thakur JD, Dossani RH, Sharma K, Nanda A, Guthikonda B. Nixon M, et al. World Neurosurg. 2018 Jan;109:152-159. doi: 10.1016/j.wneu.2017.09.131. Epub 2017 Sep 28. World Neurosurg. 2018. PMID: 28962961 Review.
OBJECTIVE: Natalizumab, a selective adhesion molecule inhibitor binding to an alpha-4 subunit of integrin, has emerged to be an effective immunomodulator, especially in the treatment of relapsing-remitting multiple sclerosis and Crohn disease. Recent reports documenting the devel …
OBJECTIVE: Natalizumab, a selective adhesion molecule inhibitor binding to an alpha-4 subunit of integrin, has emerged to be an effective im …
Updates on Primary Central Nervous System Lymphoma.
Schaff LR, Grommes C. Schaff LR, et al. Curr Oncol Rep. 2018 Feb 28;20(2):11. doi: 10.1007/s11912-018-0666-1. Curr Oncol Rep. 2018. PMID: 29492682 Free PMC article. Review.
PURPOSE OF REVIEW: Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy confined to the brain, spinal cord, leptomeninges, and eyes. ...New, exciting strategies are in development and when feasible, enrollment in a clin …
PURPOSE OF REVIEW: Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy confined t …
754 results